Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01610596 · ClinicalTrials.gov registry record · Phase 2
A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis
A Phase 2 study, sponsored by Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT01610596 is a Phase 2 study that has completed, run by Therapeutics. The registered enrollment target is 72 participants.
The verdict
NCT01610596, a Phase 2 study, has completed, sponsored by Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
This is a double-blind, multicenter, vehicle-controlled, parallel group comparison study to determine and compare the efficacy and safety of HBP Lotion 0.05% and Vehicle Lotion applied twice daily for two weeks in subjects with moderate to severe plaque psoriasis. Eligible subjects will be randomized (1:1) to one of two treatment groups - HBP Lotion 0.05% or Vehicle Lotion. The maximum amount of test article to be applied per week should not exceed 50 grams.
Interventions
- DRUG Placebo
- DRUG Halobetasol Propionate Lotion 0.05%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01610596
The ClinicalTrials.gov registry entry for NCT01610596 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01610596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01610596 about?
NCT01610596 is a clinical study titled "A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis". This is a double-blind, multicenter, vehicle-controlled, parallel group comparison study to determine and compare the efficacy and safety of HBP Lotion 0.05% and Vehicle Lotion applied twice daily for two weeks in subjects with moderate to severe plaque psoriasis. Eligible subjects will be randomize...
What is the current status of trial NCT01610596?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2011-11. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01610596?
The interventions under investigation include: Placebo (DRUG), Halobetasol Propionate Lotion 0.05% (DRUG).
Who is sponsoring clinical trial NCT01610596?
This trial is sponsored by Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.